To control EGFR and VEGF signal pathways, the dual-targeted approach combining erlotinib (EGFR TKI) with bevacizumab demonstrated superior antitumor activity compared to monotherapy in clinical practice, leading to its approval as a first-line treatment option for EGFR-mutant NSCLC (19, 24). Here, EGFR is linked to non-small cell lung carcinoma.